Genmab

Research Genmab (GMAB) on Bullrun: valuation model: 26.2% undervalued, market cap USD 15.97B, P/E 19.6. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerGMAB
• ExchangeNASDAQ
• CountryDenmark
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Valuation signal26.2% undervalued
• Market capUSD 15.97B
• P/E19.6
• Financial periodQ1 2026
• RevenueUSD 896.00M
• Net incomeUSD 821.00M
• Free cash flowUSD 872.00M
• Gross margin406.3%

Valuation Snapshot

Bullrun's latest valuation model marks Genmab as 26.2% undervalued; latest market cap is USD 15.97B; P/E is 19.6.

About Genmab

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy.

Frequently asked questions

Is Genmab overvalued or undervalued?

Bullrun's valuation model currently marks Genmab as 26.2% undervalued.

What is Genmab's market cap?

Genmab's market capitalization is USD 15.97B.

What is Genmab's P/E ratio?

Genmab's price-to-earnings (P/E) ratio is 19.6.

What does Genmab do?

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark.